BIO Q3'26 Earnings: revenue estimate is 649.94M USD

What happened

Bio-Rad Laboratories is scheduled to report third-quarter 2026 results on November 4 after the market closes. The revenue estimate is 649.94 million USD, and the earnings-per-share estimate, meaning profit per share, is 2.23 USD.

Confirmed

Global impact / market context

Investors will compare actual revenue and profit per share against these estimates. A miss or beat can change how the stock is valued, because future cash available and management guidance shape expectations for costs, capital spending, and returns to shareholders.

Analyst inference

Bio-Rad has recently exceeded revenue estimates in prior quarters, which may raise expectations for this report. The profit-per-share estimate of 2.23 USD gives a clear target for judging whether recent profit trends continue.

Analyst inference

What to watch

1. Revenue estimate is 649.94 million USD and EPS estimate is 2.23 USD; compare reported figures against these to judge whether the quarter beat or missed expectations. Confirmed
2. Watch management guidance on costs and capital spending, which means money for long-term investments, for signals on future revenue and profit per share beyond the quarter. Proposed
3. Track the gap between reported and estimated profit per share versus prior quarters, because repeated profit beats or misses can shift investor positioning in the stock. Analyst inference

Evidence

• Original source link unavailable